ICON plc announced a halt in its large-scale next-generation COVID vaccine study, following a stop work notice issued by BARDA to the sponsor. This development affects the study that had resumed on July 24, 2025, and was actively enrolling participants. As per the current status, approximately 5,000 of the planned 10,000 subjects have been enrolled and dosed. These participants will continue to be monitored according to the study protocol. Discussions between the sponsor and BARDA are ongoing to determine the next steps. Despite the halt impacting projected revenue for the latter half of 2025, ICON plc maintains its financial guidance for the full year. The company cautions against placing undue reliance on forward-looking statements due to inherent uncertainties and risks.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.